

## Alembic Pharma

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	ALPM IN
Equity Shares (m)	197
M.Cap.(INRb)/(USDb)	186 / 2.1
52-Week Range (INR)	1304 / 725
1, 6, 12 Rel. Per (%)	-2/2/-23
12M Avg Val (INR M)	299

### Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	66.7	71.8	79.0
EBITDA	10.1	12.2	14.4
Adj. PAT	5.7	7.2	8.8
EBIT Margin (%)	11.0	12.6	13.8
Cons. Adj. EPS (INR)	29.1	36.4	44.8
EPS Gr. (%)	-7.4	25.1	23.1
BV/Sh. (INR)	264.1	294.9	334.0
<b>Ratios</b>			
Net D:E	0.2	0.2	0.1
RoE (%)	11.5	12.9	14.1
RoCE (%)	10.9	11.8	12.9
Payout (%)	20.3	16.5	13.4
<b>Valuations</b>			
P/E (x)	33.2	26.5	21.5
EV/EBITDA (x)	19.9	16.4	13.6
Div. Yield (%)	0.5	0.5	0.5
FCF Yield (%)	1.5	2.9	3.4
EV/Sales (x)	3.0	2.8	2.5

### Shareholding pattern (%)

As On	Jun-25	Mar-25	Jun-24
Promoter	69.7	69.7	69.6
DII	16.5	16.4	15.5
FII	4.0	3.9	4.3
Others	9.9	10.0	10.6

FII Includes depository receipts

**CMP: INR947**

**TP: INR990 (+5%)**

**Neutral**

### Export strength offsets muted DF/API show

#### Re-assessing DF business for higher productivity and sustainable growth

- Alembic Pharma (ALPM) delivered a largely in-line performance for 1QFY26. Superior execution in the export market led to YoY growth in revenue/EBITDA/PAT for the quarter. This benefit was offset, to some extent, by a muted show in the domestic formulation (DF) and API segments.
- ALPM sustained its growth momentum in the US market on the back of new launches. Notably, upcoming introductions such as g-Entresto have the potential to further strengthen growth in the US generics segment. That said, a broader scope of business would be necessary to enhance capacity utilization and, in turn, improve the profitability of the US generics segment.
- Growth of non-US exports has been broad-based across focus markets.
- The DF segment continues to struggle with growth. In 1QFY26, ALPM undertook measures to address certain challenges in this segment, which impacted the growth of the DF segment's specialty category.
- We tweak our estimates for FY26/FY27 (+3%/+2%), factoring in: a) improved business prospects in the export market and b) near-term disruption in the DF segment. We value ALPM 22x 12M forward earnings to arrive at a TP of INR990.
- After a muted performance in FY25, ALPM is working to improve business prospects across its key markets. Growth in export markets is strengthening on the back of new launches and superior supply chain management. However, this is being offset to some extent by an inferior show in the DF and API segments. Considering these aspects, we expect a 24% earnings CAGR over FY25-27. The current valuation largely factors in the earnings upside. Hence, we reiterate a Neutral rating on the stock.

### In-line 1Q; margin gain from product mix supports PAT growth

- ALPM sales grew 9.5% YoY to INR17b (in line).
- US generics sales grew 13% YoY to INR5.2b (USD61m; 31% of sales). Ex-US generics, export sales grew 21% YoY to INR3.3b (19% of sales). DF sales grew 5% YoY to INR6b (35% of sales).
- API sales were stable YoY at INR2.6b (15% of sales).
- Gross margin expanded 140bp YoY to 76% due to a better product mix.
- EBITDA margin expanded 130bp YoY to 16.4% (in line), led by a better gross margin. Higher R&D spend (+150bp YoY as a % of sales) was offset by lower other expenses (down 170bp as a % of sales).
- Consequently, EBITDA grew 19% YoY to INR2.8b (our est: INR2.7b).
- Adj. PAT grew 14.6% YoY to INR1.5b (in line).

### Key highlights from the management commentary

- ALPM has guided for US sales to grow 10-15% YoY in FY26.
- Non-US sales are also guided to grow at 10-15% YoY in FY26.
- ALPM is addressing certain challenges in the DF business and has gained better control over channel inventory for its products. This, however, impacted specialty segment growth for the quarter.
- Data leakage by certain Chinese traders regarding exports from India has impacted ALPM's API business.
- APLM expects to launch 4-5 products in the US in 2QFY26.
- Gross/net debt stood at INR11.8b/INR9.7b at the end of 1QFY26.

### Quarterly perf. (Consol.)

Y/E March	(INR m)											
	FY25				FY26E				FY25	FY26E	FY26E	
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1Q	vs Est
<b>Net Sales</b>	<b>15,617</b>	<b>16,480</b>	<b>16,927</b>	<b>17,696</b>	<b>17,107</b>	<b>17,963</b>	<b>18,313</b>	<b>18,645</b>	<b>66,721</b>	<b>72,028</b>	<b>17,086</b>	<b>0.1%</b>
YoY Change (%)	5.1	3.3	3.8	16.7	9.5	9.0	8.2	5.4	7.1	8.0	9.4	
Total Expenditure	13,249	14,087	14,325	14,977	14,294	14,819	15,035	15,409	56,639	59,557	14,352	
<b>EBITDA</b>	<b>2,368</b>	<b>2,393</b>	<b>2,602</b>	<b>2,719</b>	<b>2,813</b>	<b>3,144</b>	<b>3,278</b>	<b>3,237</b>	<b>10,082</b>	<b>12,471</b>	<b>2,734</b>	<b>2.9%</b>
YoY Change (%)	19.2	14.9	-2.4	4.6	18.8	31.4	26.0	19.0	8.0	23.7	15.4	
Margins (%)	15.2	14.5	15.4	15.4	16.4	17.5	17.9	17.4	15.1	17.3	16.0	
Depreciation	690	705	700	690	738	800	816	831	2,786	3,184	762	
<b>EBIT</b>	<b>1,678</b>	<b>1,688</b>	<b>1,902</b>	<b>2,029</b>	<b>2,075</b>	<b>2,343</b>	<b>2,462</b>	<b>2,406</b>	<b>7,297</b>	<b>9,287</b>	<b>1,972</b>	<b>5.3%</b>
YoY Change (%)	26.6	19.9	-3.6	6.5	23.7	38.9	29.5	18.6	10.4	27.3	17.5	
Interest	132	188	223	245	235	215	205	186	788	841	230	
Other Income	21	167	95	142	65	167	171	277	425	680	155	
<b>PBT before EO expense</b>	<b>1,567</b>	<b>1,667</b>	<b>1,774</b>	<b>1,926</b>	<b>1,905</b>	<b>2,295</b>	<b>2,428</b>	<b>2,497</b>	<b>6,934</b>	<b>9,125</b>	<b>1,897</b>	<b>0.4%</b>
Extra-Ord expense	0	-129	0	0	0	0	0	0	129	0	0	
<b>PBT</b>	<b>1,567</b>	<b>1,796</b>	<b>1,774</b>	<b>1,926</b>	<b>1,905</b>	<b>2,295</b>	<b>2,428</b>	<b>2,497</b>	<b>7,063</b>	<b>9,125</b>	<b>1,897</b>	<b>0.4%</b>
Tax	225	273	401	353	365	418	440	449	1,252	1,671	343	
Rate (%)	14.4	15.2	22.6	18.3	19.1	18.2	18.1	18.0	17.7	18.3	18.1	
MI & P/L of Asso. Cos.	-5	-11	-11	4	-3	7	9	11	-23	24	5	
<b>Reported PAT</b>	<b>1,347</b>	<b>1,534</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,871</b>	<b>1,980</b>	<b>2,036</b>	<b>5,834</b>	<b>7,430</b>	<b>1,549</b>	<b>-0.3%</b>
<b>Adj PAT</b>	<b>1,347</b>	<b>1,425</b>	<b>1,384</b>	<b>1,569</b>	<b>1,544</b>	<b>1,871</b>	<b>1,980</b>	<b>2,036</b>	<b>5,725</b>	<b>7,430</b>	<b>1,549</b>	<b>-0.3%</b>
YoY Change (%)	11.6	3.6	-23.5	-12.3	14.6	31.3	43.0	29.8	-7.4	29.8	15.0	
Margins (%)	8.6	8.6	8.2	8.9	9.0	10.4	10.8	10.9	8.6	10.3	9.1	
<b>EPS</b>	<b>6.9</b>	<b>7.2</b>	<b>7.0</b>	<b>8.0</b>	<b>7.9</b>	<b>9.5</b>	<b>10.1</b>	<b>10.4</b>	<b>29.1</b>	<b>36.4</b>	<b>7.9</b>	


### Key performance indicators (Consolidated)

Y/E March	(INR m)											
	FY25				FY26E				FY25	FY26E	FY26E	Var %
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	1QE	2QE	1QE	vs Est
<b>India</b>	<b>5,720</b>	<b>6,090</b>	<b>6,140</b>	<b>5,450</b>	<b>5,990</b>	<b>6,404</b>	<b>6,447</b>	<b>5,874</b>	<b>23,400</b>	<b>24,715</b>	<b>5900</b>	<b>2%</b>
YoY Change (%)	9.2	5.5	3.0	8.3	4.7	5.2	5.0	7.8	6.4	5.6	3.1	
<b>Exports</b>	<b>7,320</b>	<b>7,650</b>	<b>8,200</b>	<b>8,830</b>	<b>8,510</b>	<b>8,690</b>	<b>8,965</b>	<b>9,505</b>	<b>32,000</b>	<b>35,670</b>	<b>8,441</b>	<b>1%</b>
YoY Change (%)	11.4	9.9	9.9	28.9	16.3	13.6	9.3	7.6	15.0	11.5	15.3	
<b>APIs</b>	<b>2,590</b>	<b>2,740</b>	<b>2,590</b>	<b>3,420</b>	<b>2,610</b>	<b>2,850</b>	<b>2,901</b>	<b>3,266</b>	<b>11,340</b>	<b>11,627</b>	<b>2,745</b>	<b>-5%</b>
YoY Change (%)	(15.1)	(14.9)	(10.4)	3.6	0.8	4.0	12.0	(4.5)	(9.0)	2.5	6.0	
<b>Cost Break-up</b>												
RM Cost (% of Sales)	25.2	26.0	26.0	30.0	23.8	28.2	28.0	29.0	26.9	27.3	29.0	
Staff Cost (% of Sales)	24.3	23.8	23.5	22.2	24.7	22.4	22.2	22.4	23.4	22.9	22.4	
R&D Expenses (% of Sales)	7.0	8.0	7.0	9.1	8.5	8.2	8.3	8.0	7.8	8.2	8.0	
Other Cost (% of Sales)	28.3	27.7	28.2	23.3	26.5	23.7	23.6	23.2	26.8	24.2	23.2	
<b>Gross Margins (%)</b>	<b>74.8</b>	<b>74.0</b>	<b>74.0</b>	<b>70.0</b>	<b>76.2</b>	<b>71.8</b>	<b>72.0</b>	<b>71.0</b>	<b>73.1</b>	<b>72.7</b>	<b>71.0</b>	
<b>EBITDA Margins (%)</b>	<b>15.2</b>	<b>14.5</b>	<b>15.4</b>	<b>15.4</b>	<b>16.4</b>	<b>17.5</b>	<b>17.9</b>	<b>17.4</b>	<b>15.1</b>	<b>17.3</b>	<b>17.4</b>	
<b>EBIT Margins (%)</b>	<b>10.7</b>	<b>10.2</b>	<b>11.2</b>	<b>11.5</b>	<b>12.1</b>	<b>13.0</b>	<b>13.4</b>	<b>12.9</b>	<b>10.9</b>	<b>12.9</b>	<b>12.9</b>	

E: MOFSL Estimates


## Key exhibits

**Exhibit 1: DF sales grew 4.7% YoY in 1QFY26**




Source: MOFSL, Company

**Exhibit 2: International business grew 16.3% YoY**




Source: MOFSL, Company

**Exhibit 3: Sales increased 9.5% YoY for 1QFY26**



Source: MOFSL, Company

**Exhibit 4: EBITDA margin expanded 130bp YoY in 1QFY26**



Source: MOFSL, Company



## Conference call highlights

- ALPM has not witnessed any channel stockings for its portfolio in the recent past in anticipation of tariffs.
- G-entresto is a notable launch for ALPM. In-house API manufacturing provides potential for both market share gains and improved profitability for this product.
- Despite pricing pressures in US generics, ALPM has posted YoY growth in the segment due to a higher volume off-take.
- While gross margin of the US generics business is encouraging, EBITDA margin is relatively lower due to lower capacity utilizations related to injectables/derma/new capacity for oral solids.
- The commissioning of the Indore plant led to a higher depreciation for the quarter.

## Exports drive near-term momentum; DF/API keeps outlook balanced

### US: Specialty focus and launch momentum to drive better sales growth

- The launch momentum continued in the US, driving 11% YoY growth in 1QFY26, reaching USD61m.
- Post 16 launches in FY25, ALPM launched four ANDAs in 1QFY26 with a target of 20 product filings in FY26.
- Interestingly, the filings are spread in terms of dosages (24 OSDs, 11 injectables, 6 Ophthalmics, and 5 dermatology by the end of Mar'25).
- ALPM's R&D team is working on high-growth therapy such as oncology and dermatology, with 75 molecules in the pipeline and 35-40% in the non-oral solid dosage formulation. This implies complexity to manufacturing and, thus, fewer entry barriers, thereby driving better profitability.
- ALPM filed 2 ANDAs and received approvals for 6 ANDAs in 1QFY26.
- Notably, the capex required to cater to the manufacturing needs will be largely completed and going forward, only maintenance capex will be required over the medium term.
- From the approved portfolio, ALPM has a total of 223 approved ANDAs, comprising 153 oral solids, 30 dermatological products, 20 ophthalmic formulations, 18 injectables, and 2 inhalation products.
- Considering the new launches of complex products and a scale-up in existing products, we expect a 14% sales CAGR over FY25-27, reaching USD306m.

### India: Acute outperforms, while specialty underperforms in 1QFY26


- The DF business has been witnessing moderate 6.7% growth on annual basis for the past three years. Specifically, for 1QFY26, the DF business came in at INR6b, up 5% YoY.
- 1QFY26 is the second consecutive quarter to reflect better growth in acute therapy (+6% YoY). After healthy performance for almost 19 quarters, the specialty segment was stable YoY in 1QFY26. Animal health continued its growth momentum, posting a 16% YoY growth in the quarter.
- ALPM's specialty focus continues on gynaecology, anti-diabetes, ophthalmology, and dermatology, enabling it to outpace the industry.
- ALPM is working to improve customer orientation behavior among the sales force to enhance its market share. It is also using Artificial intelligence (AI) for better productivity.
- Moreover, the addition of sales force is expected to drive better outlook in the DF segment going forward.
- Over the past 12M, ALPM's prescription base has been 131m.
- We expect a 6% sales CAGR over FY25-27, reaching INR26.2b.

### Reiterate Neutral

- We tweak our estimates for FY26/FY27 (+3%/+2%), factoring in: a) improved business prospects in the exports market and b) near-term disruption in the DF segment. We value ALPM 22x 12M forward earnings to arrive at a TP of INR990.
- After a muted performance in FY25, ALPM is working to improve business prospects across its key markets. Growth in exports markets is strengthening on the back of new launches and superior supply chain management. However, this is being offset to some extent by an inferior show in the DF and API segments. Considering these aspects, we expect a 24% earnings CAGR over FY25-27. The


current valuation largely factors in the earnings upside. Hence, we reiterate a Neutral rating on the stock.

**Exhibit 5: P/E chart**



Source: MOFSL, Company, Bloomberg


**Exhibit 6: EV/EBITDA chart**



Source: MOFSL, Company, Bloomberg


## Story in charts

**Exhibit 7: Formulation sales to post 9.6% CAGR over FY25-27**




Source: MOFSL, Company

**Exhibit 8: Expect DF to post 6% CAGR over FY25-27**




Source: MOFSL, Company

**Exhibit 9: EBITDA CAGR to remain at 19.5% over FY25-27**




Source: MOFSL, Company

**Exhibit 10: R&D expenses as a % of sales to remain stable over FY25-27**




Source: MOFSL, Company

**Exhibit 11: EBITDA margins to expand over FY25-27**



**Exhibit 12: Earnings CAGR to remain at 24% over FY25-27**



## Financials and valuations

Consolidated - Income Statement								(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Net Sales</b>	<b>46,060</b>	<b>53,931</b>	<b>53,058</b>	<b>56,526</b>	<b>62,290</b>	<b>66,740</b>	<b>71,803</b>	<b>78,997</b>
Change (%)	17.0	17.1	-1.6	6.5	10.2	7.1	7.6	10.0
<b>EBITDA</b>	<b>12,233</b>	<b>15,575</b>	<b>9,972</b>	<b>8,194</b>	<b>9,337</b>	<b>10,102</b>	<b>12,246</b>	<b>14,436</b>
Change (%)	39.9	27.3	-36.0	-17.8	14.0	8.2	21.2	17.9
Margin (%)	26.6	28.9	18.8	14.5	15.0	15.1	17.1	18.3
Depreciation	1,573	1,835	2,218	2,314	2,727	2,786	3,184	3,543
<b>EBIT</b>	<b>10,660</b>	<b>13,741</b>	<b>7,754</b>	<b>5,880</b>	<b>6,611</b>	<b>7,316</b>	<b>9,062</b>	<b>10,894</b>
Int. and Finance Charges	272	160	177	502	562	788	841	798
Other Income - Rec.	49	100	505	27	283	425	680	710
<b>PBT bef. EO Exp.</b>	<b>10,437</b>	<b>13,681</b>	<b>8,081</b>	<b>5,405</b>	<b>6,332</b>	<b>6,953</b>	<b>8,901</b>	<b>10,806</b>
EO Expense/(Income)	436	0	1,880	1,550	0	-129	0	0
<b>PBT after EO Exp.</b>	<b>10,001</b>	<b>13,681</b>	<b>6,201</b>	<b>3,855</b>	<b>6,332</b>	<b>7,082</b>	<b>8,901</b>	<b>10,806</b>
Current Tax	2,046	2,629	1,279	42	658	1,629	2,047	2,485
Deferred Tax	-54	-96	-235	84	-498	-377	-376	-562
Tax Rate (%)	19.9	18.5	16.8	3.3	2.5	17.7	18.8	17.8
MI & P/L of Asso. Cos.	-284.7	-633.5	-300.3	309.2	-9.8	-5.4	69.0	72.0
<b>Reported PAT</b>	<b>8,294</b>	<b>11,781</b>	<b>5,457</b>	<b>3,420</b>	<b>6,182</b>	<b>5,836</b>	<b>7,160</b>	<b>8,811</b>
<b>PAT Adj for EO items</b>	<b>8,643</b>	<b>11,781</b>	<b>6,889</b>	<b>4,296</b>	<b>6,182</b>	<b>5,725</b>	<b>7,160</b>	<b>8,811</b>
Change (%)	47.7	36.3	-41.5	-37.6	43.9	-7.4	25.1	23.1
Margin (%)	18.8	21.8	13.0	7.6	9.9	8.6	10.0	11.2

Consolidated - Balance Sheet								(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	377	393	393	393	393	393	393	393
Total Reserves	31,820	50,883	51,982	43,312	47,789	51,516	57,563	65,263
Preference Capital	0	0	0	0	0	0	0	0
<b>Net Worth</b>	<b>32,197</b>	<b>51,276</b>	<b>52,375</b>	<b>43,705</b>	<b>48,182</b>	<b>51,909</b>	<b>57,956</b>	<b>65,656</b>
Minority Interest	-290	-606	0	0	0	-14	-14	-14
Deferred Liabilities	122	42	0	0	0	189	-187	-749
Total Loans	18,208	2,715	7,021	7,051	4,933	12,423	12,325	12,227
<b>Capital Employed</b>	<b>50,237</b>	<b>53,426</b>	<b>59,397</b>	<b>50,756</b>	<b>53,115</b>	<b>64,508</b>	<b>70,080</b>	<b>77,120</b>
Gross Block	20,700	24,909	27,221	35,532	39,741	42,295	52,078	56,928
Less: Accum. Deprn.	5,181	7,016	9,234	11,548	14,274	17,060	20,244	23,787
<b>Net Fixed Assets</b>	<b>15,518</b>	<b>17,893</b>	<b>17,987</b>	<b>23,985</b>	<b>25,467</b>	<b>25,235</b>	<b>31,833</b>	<b>33,141</b>
Capital WIP	18,462	21,817	23,034	6,013	5,244	8,372	3,590	4,740
<b>Total Investments</b>	<b>179</b>	<b>2,363</b>	<b>1,184</b>	<b>963</b>	<b>930</b>	<b>1,272</b>	<b>1,272</b>	<b>1,272</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>25,734</b>	<b>25,017</b>	<b>29,015</b>	<b>30,868</b>	<b>32,815</b>	<b>42,850</b>	<b>46,178</b>	<b>52,321</b>
Inventory	11,875	14,862	16,097	14,753	16,435	22,881	25,862	26,588
Account Receivables	8,648	3,486	8,071	10,464	10,248	13,998	14,557	15,367
Cash and Bank Balance	808	1,058	694	823	1,266	901	671	5,255
Loans and Advances	4,404	5,612	4,153	4,828	4,866	5,070	5,087	5,111
<b>Curr. Liability &amp; Prov.</b>	<b>9,656</b>	<b>13,663</b>	<b>11,824</b>	<b>11,073</b>	<b>11,341</b>	<b>13,222</b>	<b>12,793</b>	<b>14,353</b>
Account Payables	6,259	6,688	7,064	6,798	7,356	8,799	8,551	9,749
Other Current Liabilities	2,270	5,601	3,165	2,512	2,237	2,321	2,497	2,747
Provisions	1,127	1,375	1,595	1,763	1,748	2,102	1,744	1,857
<b>Net Current Assets</b>	<b>16,078</b>	<b>11,354</b>	<b>17,192</b>	<b>19,795</b>	<b>21,474</b>	<b>29,628</b>	<b>33,385</b>	<b>37,967</b>
Misc Expenditure	0	0	0	0	0	0	0	0
<b>Appl. of Funds</b>	<b>50,238</b>	<b>53,426</b>	<b>59,397</b>	<b>50,756</b>	<b>53,115</b>	<b>64,508</b>	<b>70,080</b>	<b>77,120</b>

## Financials and valuations

### Ratios

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Basic (INR)</b>								
EPS	<b>44.0</b>	<b>59.9</b>	<b>35.0</b>	<b>21.9</b>	<b>31.5</b>	<b>29.1</b>	<b>36.4</b>	<b>44.8</b>
Cash EPS	54.2	69.3	46.3	33.6	45.3	43.3	52.6	62.8
BV/Share	170.8	260.9	266.5	222.4	245.1	264.1	294.9	334.0
DPS	10.0	10.4	10.4	4.2	5.2	5.2	5.2	5.2
Payout (%)	27.4	20.1	43.4	27.7	19.1	20.3	16.5	13.4
<b>Valuation (x)</b>								
P/E	22.0	16.1	27.6	44.2	30.7	33.2	26.5	21.5
Cash P/E	17.8	13.9	20.9	28.7	21.3	22.3	18.4	15.4
P/BV	5.7	3.7	3.6	4.3	3.9	3.7	3.3	2.9
EV/Sales	4.5	3.5	3.7	3.5	3.1	3.0	2.8	2.5
EV/EBITDA	16.9	12.3	19.7	23.9	20.7	19.9	16.4	13.6
Dividend Yield (%)	1.0	1.1	1.1	0.4	0.5	0.5	0.5	0.5
<b>Return Ratios (%)</b>								
RoE	30.1	29.7	13.9	8.3	13.5	11.5	12.9	14.1
RoCE	19.7	21.6	12.1	10.4	12.9	10.9	11.8	12.9
RoIC	34.6	38.0	20.6	14.7	14.5	12.1	12.4	13.7
<b>Working Capital Ratios</b>								
Asset Turnover (x)	0.9	1.0	0.9	1.1	1.2	1.0	1.0	1.0
Inventory (Days)	94	101	111	95	96	125	131	123
Debtor (Days)	69	24	56	68	60	77	74	71
Creditor (Days)	50	45	49	44	43	48	43	45
<b>Leverage Ratio (x)</b>								
Net Debt/Equity	0.5	0.0	0.1	0.1	0.1	0.2	0.2	0.1

### Consolidated - Cash Flow Statement

(**INRm**)

Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Net Profit / (Loss) Before Tax	9,998	13,681	6,201	3,546	6,318	7,072	8,901	10,806
Depreciation	1,573	1,835	2,868	2,754	2,727	2,786	3,184	3,543
Interest & Finance Charges	272	160	131	502	562	788	161	88
Direct Taxes Paid	2,361	2,454	1,234	607	199	714	2,047	2,485
(Inc)/Dec in WC	-5,844	2,395	-3,673	-576	-957	-9,214	-3,986	1
<b>CF from Operations</b>	<b>3,638</b>	<b>15,617</b>	<b>4,292</b>	<b>5,619</b>	<b>8,452</b>	<b>718</b>	<b>6,213</b>	<b>11,952</b>
Others	853	-983	1,231	1,620	-819	383	0	0
<b>CF from Operating incl EO</b>	<b>4,491</b>	<b>14,634</b>	<b>5,524</b>	<b>7,239</b>	<b>7,633</b>	<b>1,101</b>	<b>6,213</b>	<b>11,952</b>
(Inc)/dec in FA	-6,726	-6,592	-4,243	-4,434	-3,159	-5,539	-5,000	-6,000
<b>Free Cash Flow</b>	<b>-2,235</b>	<b>8,041</b>	<b>1,281</b>	<b>2,805</b>	<b>4,474</b>	<b>-4,437</b>	<b>1,213</b>	<b>5,952</b>
(Pur)/Sale of Investments	23	-1,796	523	-64	-63	55	0	0
Others	-613	0	17	22	32	-146	680	710
<b>CF from Investments</b>	<b>-7,316</b>	<b>-8,388</b>	<b>-3,702</b>	<b>-4,476</b>	<b>-3,190</b>	<b>-5,629</b>	<b>-4,320</b>	<b>-5,290</b>
Issue of Shares	0	0	0	0	0	0	0	0
(Inc)/Dec in Debt	5,919	-12,398	1,300	-172	-2,312	7,385	-98	-98
Interest Paid	-1,111	6,611	-519	-497	-494	-786	-841	-798
Dividend Paid	-3,260	0	-2,752	-1,966	-1,573	-2,162	-1,183	-1,183
<b>CF from Fin. Activity</b>	<b>1,576</b>	<b>-5,994</b>	<b>-2,186</b>	<b>-2,635</b>	<b>-4,379</b>	<b>4,437</b>	<b>-2,122</b>	<b>-2,079</b>
<b>Inc/Dec of Cash</b>	<b>-1,249</b>	<b>252</b>	<b>-364</b>	<b>129</b>	<b>64</b>	<b>-91</b>	<b>-229</b>	<b>4,583</b>
Add: Beginning Balance	2,055	807	1,059	694	823	1,266	901	671
<b>Closing Balance</b>	<b>807</b>	<b>1,058</b>	<b>694</b>	<b>823</b>	<b>887</b>	<b>1,175</b>	<b>671</b>	<b>5,255</b>
<b>Total Cash and Cash Eq</b>	<b>807</b>	<b>1,059</b>	<b>694</b>	<b>823</b>	<b>1,266</b>	<b>901</b>	<b>671</b>	<b>5,255</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/ListOf200of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may: (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

\*\*\*\*\*

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com).

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com), for DP to [dpgrievances@motilaloswal.com](mailto:dpgrievances@motilaloswal.com).